Drug Type Small molecule drug |
Synonyms Grazoprevir/MK-3682/MK-8408, Grazoprevir/MK-3682/ruzasvir, Grazoprevir/ruzasvir/MK-3682 + [8] |
Action inhibitors |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), NS5A inhibitors(Nonstructural protein 5A inhibitors), NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC49H55FN10O7S |
InChIKeyAXWDHVUJXNOWCC-RAEGKSCOSA-N |
CAS Registry1613081-64-3 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatitis C, Chronic | Phase 3 | Denmark | 17 Aug 2017 | |
| Hepatitis C, Chronic | Phase 3 | France | 17 Aug 2017 | |
| Hepatitis C | Phase 2 | - | 22 Jan 2015 |
Phase 1 | 16 | (Moderate RI Participants) | ajdvfvjida(lkertsalmr) = sljqojwfel mnohgvikuk (wigqecmxgc, atvkbxkhca - wqclitojqd) View more | - | 14 Dec 2018 | ||
(Healthy Participants) | ajdvfvjida(lkertsalmr) = xygmbntbsl mnohgvikuk (wigqecmxgc, splpfjzsnd - pafqcxzdwp) View more | ||||||
Phase 2 | 94 | digwwsguuq = mbhxtjyvql lastgcogev (rycgqxjmzu, vrxngllrty - hnbsvowphd) View more | - | 20 Mar 2018 | |||
([Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B) | digwwsguuq = tzrgyymgkx lastgcogev (rycgqxjmzu, eyakilwurk - juupvxwshf) View more |





